BIM-IOL System
Reduction of elevated IOP in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) undergoing cataract surgery
Key Facts
About SpyGlass Pharma
SpyGlass Pharma is a clinical-stage company with a mission to revolutionize ophthalmologic care by integrating long-acting glaucoma therapy into standard cataract surgery, thereby eliminating patient non-adherence to topical drops. Its core achievement is the development of the BIM-IOL System, a combination product delivering bimatoprost for multi-year intraocular pressure control, which has advanced to Phase 3 clinical trials. The company's strategy leverages established surgical workflows and a well-validated drug to address a large, dual-diagnosis patient population, positioning it to capture significant value in the glaucoma and cataract surgery markets.
View full company profile